Skip to main content
EJNMMI Research
Fig. 1 | EJNMMI Research

Fig. 1

From: Early 18F-FDG uptake as a reliable imaging biomarker of T790M-mediated resistance but not MET amplification in non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors

Fig. 1

Representative scheme of treatment in H1975- and H1993-tumor-bearing animals. NSCLC animal models of T790M-mediated resistance (H1975) were treated by oral gavage with 50 mg/kg erlotinib, WZ4002, or vehicle whereas mice bearing xenografts with MET amplification (H1993) were treated with 50 mg/kg erlotinib, crizotinib, or vehicle. Treatment was started 3 h after the baseline 18F-FDG PET/CT scan on day 1 and was stopped 3 h before post-treatment scan on day 3

Back to article page